The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount ...
The combination of two HER2-targeting drugs – Seagen's oral Tukysa and Roche's intravenous antibody-drug conjugate (ADC) Kadcyla – has shown a benefit over Kadcyla alone as a second-line ...
It launched Ujvira, (Trastuzumab Emtansine biosimilar) in India, which is the first biosimilar of an Antibody Drug Conjugate (ADC) Kadcyla and a highly effective drug for treatingboth early and ...
6367.T Daikin Industries,Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback